Amarin (NASDAQ:AMRN) Posts Earnings Results, Misses Estimates By $0.06 EPS

Amarin (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06), Zacks reports. Amarin had a negative net margin of 15.51% and a negative return on equity of 2.99%.

Here are the key takeaways from Amarin’s conference call:

• Positive Sentiment: International momentum accelerated, with in-market VASCEPA demand up 59% globally and 69% in Europe year over year. Recordati has launched in 11 European countries, while approvals in Singapore and South Korea are expected to support launches in 2027.
• Positive Sentiment: The U.S. business remains profitable and cash-generating despite generic pricing pressure. VASCEPA’s share of the icosapent ethyl market increased to 48% from 43% a year earlier, and branded prescriptions rose 14% in Q2.
• Positive Sentiment: Amarin generated $7 million of operating cash flow in Q2, its third consecutive positive quarter, and ended June with $314.6 million in cash and investments, no debt, and a $12 million improvement from year-end. Management continues to expect positive cash flow for full-year 2026.
• Positive Sentiment: The restructuring is complete and reduced operating expenses by 59% year over year, excluding restructuring charges by 38%, in line with the company’s approximately $70 million annual cost-savings target. Inventory also declined by $31.8 million from year-end, supporting working-capital discipline.
• Negative Sentiment: Total Q2 revenue fell to $42.2 million from $72.7 million, partly because the prior-year period included a $25 million Recordati upfront payment. Product revenue also declined to $39.1 million from $46.6 million, while higher volumes and the PBM relationship increased cost of goods sold by 22%.

Amarin Stock Up 2.0%

Shares of Amarin stock traded up $0.28 on Wednesday, hitting $14.23. The company’s stock had a trading volume of 28,384 shares, compared to its average volume of 78,496. Amarin has a 52-week low of $12.96 and a 52-week high of $20.90. The firm has a fifty day moving average price of $14.89 and a 200-day moving average price of $14.89. The company has a market capitalization of $298.51 million, a P/E ratio of -21.90 and a beta of 0.80.

Analyst Upgrades and Downgrades

AMRN has been the topic of several recent analyst reports. Zacks Research upgraded shares of Amarin from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 16th. Wall Street Zen downgraded shares of Amarin from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Hedge Funds Weigh In On Amarin

Several hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its position in Amarin by 449,522.1% during the first quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock worth $815,000 after acquiring an additional 1,811,574 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Amarin in the second quarter valued at approximately $623,000. Headlands Technologies LLC acquired a new stake in shares of Amarin in the second quarter valued at approximately $44,000. JPMorgan Chase & Co. increased its stake in shares of Amarin by 534.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,754 shares of the biopharmaceutical company’s stock worth $356,000 after purchasing an additional 18,324 shares in the last quarter. Finally, Banque Cantonale Vaudoise purchased a new position in shares of Amarin during the 3rd quarter worth approximately $32,000. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.